NASDAQ:INMDInMode Stock Price, Forecast & News

InMode's stock was trading at $24.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INMD stock has increased by 39.0% and is now trading at $33.91. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMode.

InMode is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for InMode.

InMode Ltd. (NASDAQ:INMD) posted its earnings results on Wednesday, May, 6th. The healthcare company reported $0.30 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.32 by $0.02. The healthcare company earned $40.44 million during the quarter, compared to analysts' expectations of $38.96 million. InMode had a net margin of 34.56% and a return on equity of 37.88%. The company's revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 earnings per share. View InMode's earnings history.

4 analysts have issued twelve-month price targets for InMode's stock. Their forecasts range from $36.00 to $55.00. On average, they anticipate InMode's stock price to reach $43.25 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View analysts' price targets for InMode.

Media coverage about INMD stock has been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. InMode earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news headlines about the healthcare company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutInMode.

InMode saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,570,000 shares, a decrease of 29.9% from the April 30th total of 2,240,000 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 1.1 days. Currently, 11.4% of the company's stock are short sold. View InMode's Current Options Chain.

Some companies that are related to InMode include LivaNova (LIVN), CONMED (CNMD), Natus Medical (NTUS), Zynex (ZYXI), BioLife Solutions (BLFS), AxoGen (AXGN), Stereotaxis (STXS), Viewray (VRAY), TransMedics Group (TMDX), BioSig Technologies (BSGM), Semler Scientific (SMLR), Cutera (CUTR), Soleno Therapeutics (SLNO), Fonar (FONR) and Edap Tms (EDAP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), salesforce.com (CRM), Trade Desk (TTD), AbbVie (ABBV), Alteryx (AYX), Micron Technology (MU), Okta (OKTA) and Square (SQ).

(INMD) raised $75 million in an IPO on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

InMode trades on the NASDAQ under the ticker symbol "INMD."

InMode's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors Inc. (1.31%), Avalon Investment & Advisory (0.41%), Morgan Stanley (0.40%), Morgan Stanley (0.40%), UBS Group AG (0.31%) and Two Sigma Investments LP (0.29%).

INMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Wells Fargo & Company MN, Mackenzie Financial Corp, UBS Group AG, JPMorgan Chase & Co., Steward Partners Investment Advisory LLC, and Fred Alger Management LLC.

INMD stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Two Sigma Investments LP, Axel Capital Management LLC, Avalon Investment & Advisory, Telemus Capital LLC, Roubaix Capital LLC, Federated Hermes Inc., and Geode Capital Management LLC.

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INMD stock can currently be purchased for approximately $33.91.

InMode has a market capitalization of $1.08 billion and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.

The official website for InMode is www.inmodemd.com.

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]